Another potential explanation may come from the recent study by Moll et al. [150] suggesting that, in contrast to common opinion, resistance to 1G TKIs in KRAS–mutated NSCLC may not be entirely caused by constitutive activation of KRAS but also by transcriptional upregulation of all the ERBB-family members. Here, KRAS is linked to non-small cell lung carcinoma.